Home/Filings/4/0001140361-21-006728
4//SEC Filing

Coiante Scott M 4

Accession 0001140361-21-006728

CIK 0001781983other

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 7:03 PM ET

Size

8.8 KB

Accession

0001140361-21-006728

Insider Transaction Report

Form 4
Period: 2021-02-25
Coiante Scott M
SVP, Chief Financial Officer
Transactions
  • Award

    Stock Option (right to Buy)

    2021-02-25+143,000143,000 total
    Exercise: $6.00Exp: 2031-02-25Common Stock (143,000 underlying)
  • Award

    Common Stock

    2021-02-25+33,00035,500 total
  • Award

    Common Stock

    2021-02-25+63,50099,000 total
Footnotes (3)
  • [F1]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
  • [F2]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
  • [F3]Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.

Issuer

Aprea Therapeutics, Inc.

CIK 0001781983

Entity typeother

Related Parties

1
  • filerCIK 0001608536

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 7:03 PM ET
Size
8.8 KB